On behalf of Hong Kong Biotechnology Organization (HKBIO), The BayHelix Group and Ausvic Capital, we’d like to update you on our progress so far for BIOHK2021. Since preparations began in early 2019, we were forced to postpone the event several times as a result of the challenges the past year had presented. Despite this, we continue to work tirelessly towards delivering a world-class, unparalleled face-to-face international biotech convention for our participants, creating a platform in Hong Kong to foster and encourage international collaboration.


Currently scheduled for 10-13 March 2021 (Thu-Sat), the event will only be held when it is safe to travel. BIOHK will provide participants with free COVID-19 tests as well as masks and hand sanitizers, and the convention itself will abide strictly by government health regulations and policies, with mandatory temperature checks on site. 


BIOHK2021 is about showcasing the latest and greatest as such we continue to update our content to remain current in the biotech field, presenting the newest and most relevant areas of discussion in the industry. If there are any topics you think we should cover, please let us know by replying to this email!

Current topics (more to be announced!)
  • COVID-19: An All-exclusive View
  • Infectious Diseases and Vaccines
  • Anti-Ageing
  • Digital Health: 5G, Big Data, Data Security, Block chain, AI, 3D Printing, Robotics, Cloud Computing, IoT
  • Modernization of Chinese Medicine
  • Microbiome & Probiotics
  • Pharma & New Drug Discovery
  • Developments Against Cancer
  • Translational Neuroscience
  • Regenerative Medicine & Immunology
  • Cardiovascular Diseases, Therapies and Diagnostics
  • Applications of Synthetic Biology
  • Translational Medical Genomics
  • Bioethics, Law and Investment: With Exclusive Information on the GBA
  • Business Development and Emergent Opportunities in Biotechnology
  • Environmental and Ocean Biotechnology
  • Diagnostics & Medical Devices
  • Precision and Personalized Medicine
  • Rare Diseases
  • Bio Design


  • 2019冠状病毒
  • 传染病和疫苗
  • 抗衰老
  • 数位健康:5G,大数据,数据安全,区块链,人工智能,3D打印,机器人,云端,物联网
  • 现代中医药
  • 微生物和益生菌
  • 新药物研发
  • 癌症
  • 转译神经科学
  • 再生医学和免疫学
  • 心血管疾病
  • 合成生物学的应用
  • 基因转译医学
  • 生物伦理、法律和投资
  • 生物科技发展和新兴机会
  • 环境和海洋生物技术
  • 诊断和医疗设备
  • 精准和个人化医学
  • 罕有病毒
  • 生物设计

Submit your abstracts and/or proposals by clicking the buttons below!


We strongly encourage everyone to submit abstracts and proposals for a chance to better inform and present work to industry leaders - from renowned scientists to key investors in the biotech field. 
We will continue to provide updated information on key developments with the convention, including our programme and the services available to you at BIOHK2021. 
BIOHK2021 is the first ever international biotech convention to be held at this scale in Hong Kong, as such we will do everything we can to ensure everyone has an enriching experience. We are aware that many of you are on the frontline in the fight against COVID-19 and our thoughts are with you during these challenging times.  
Be safe and stay healthy, we look forward to meeting you soon!
BIOHK2021 Organizers
Though the convention's been postponed we believe it has only made it better than ever, with more speakers and supporting organisations than we could ever imagine. We are delighted to announce that these speakers will now be joining us at our convention.

Raju Kucherlapati

Professor Kucherlapati is the Paul C. Cabot Professor of Genetics and Professor of Medicine at Harvard Medical School and was the first Scientific Director of the Harvard Medical School-Partners HealthCare Center for Genetics and Genomics (HPCGG).
Professor Kucherlapati has done extensive research into several different areas, including gene targeting and homologous recombination, human gene mapping, generation of physical maps of the human genome with special emphasis on human chromosome 12, development of techniques to modify genes in mammalian cells and in cloning human disease genes. 

Professor Kucherlapati founded several biotechnology companies including Cell Genesys, Abgenix (acquired by AMGEN) and Millennium (acquired by Takeda). He has been actively promoting Precision Medicine in China and is the co-chair of the International Cancer Precision Medicine Conference.

Raju Kucherlapati



Kucherlapati教授创立了多间生物技术公司,包括Cell Genesys,Abgenix(被安进收购)和Millennium(被武田薬品收购)。他一直在中国积极推广精准医学,并且是国际癌症精准医学会议的联合主席。

Wang Jun

Professor Wang Jun is the founder and CEO of GeneHarbor Biotechnologies, a company committed to the development, manufacturing and commercial application of biocatalysts (enzymes). 
Professor Wang has a Ph.D. in Molecular Biology from the University of Wisconsin-Madison. In 1992 he joined the School of Medicine at the Chinese University of Hong Kong and was promoted to professor in the Department of Biochemistry in 1999. Mainly focused on molecular biology, enzyme engineering and biosynthesis, he has engaged in biotechnology research and development and industrial production for over 40 years and is the creator of more than 80 patents.




Johnsee Lee 

Dr Johnsee Lee is the founder, CEO and president of Personal Genomics and the current Chairman of Taiwan Bio Industry Organization. Prior to this, he previously served as the President of Industrial Technology Research Institute (ITRI), Chairman of the Development Center for Biotechnology (DCB), and Board Director of Taiwan Semiconductor Manufacturing Corp (TSMC); playing a key leadership role in developing Taiwan’s high-tech industries.
Dr. Lee is also the founder and first director of the Biomedical Engineering Laboratory at ITRI and has facilitated the founding of more than 10 biotech and IT companies over the last 15 years. 
Dr. Lee has published numerous journal papers and patents, and have received awards such as the CIE Distinguished Achievement Award, National Engineering Medal, the CIE Distinguished Achievement Award, and the Innovation Leadership Award by Global Views.


李钟熙博士是体学生物科技公司的创办人,行政总裁,及主席,以及台湾生物产业发展协会现任主席。在担任该职位之前,他曾担任工业技术研究院(ITRI)总裁,财团法人生物技术开发中心(DCB)主席以及台湾积体电路制造(TSMC)董事会董事; 在发展台湾高科技产业方面发挥重要的领导角色。


李钟熙博士发表了许多期刊论文和专利,并获得多个奖项如美洲中国工程师学会大纽约区分会杰出成就奖,国家工程奖章,弗若斯特沙利文创新及研究奖及Global Views创新领导奖。

Copyright © 2020 Hong Kong Biotechnology Organisation. All rights reserved.

No longer want to receive these emails?
Unsubscribe from this list